Other substances

Cobimetinib

A protein kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Cobimetinib is a mitogen-activated protein kinase kinase 1 inhibitor. It has antineoplastic properties (NCIt). It is used in the treatment of advanced malignant melanoma (LiverTox). Cobimetinib was shown to potently inhibit SARS-CoV-2-mediated cytokine release in vitro (Chan et al., 2021).

Cobimetinib on PubChem
Cobimetinib on DrugBank
Cobimetinib on Wikipedia

Marketed as

COTELLIC

 

Structure image - Cobimetinib

C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O

Supporting references

Link Tested on Impact factor Notes Publication date
The Host Cell ViroCheckpoint: Identification and Pharmacologic Targeting of Novel Mechanistic Determinants of Coronavirus-Mediated Hijacked Cell States
Preprint 		in silico

one of the top drugs and compounds identified by ViroTreat

 May/17/2020
Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release
Spike protein Spike variant Small molecule In vitro Mechanism In silico Al 		THP1 cells-derived macrophages 11.43

SARS-CoV-2 (WT/alpha/beta/delta variant) Spike protein’s N-terminal domain induced inflammation in an in vitro model. This inflammation was effectively inhibited by the compound. 

 Sep/06/2021
Export (.csv)